Selitrectinib Inhibitor

Name: Selitrectinib Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5758331
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5758331

Selitrectinib is a potent and selective inhibitor of the receptor tyrosine kinases(TRK)(TrkA and TrkC with IC50s of 0.6 and More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Selitrectinib, Inhibitor

Full Product Name

Selitrectinib

Product Synonym Names

LOXO-195

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

380.42

Solubility

DMSO: 62.5mg/mL (164.29mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C20H21FN6O

SMILES

C[C@@H]1CCc2ncc(F)cc2[C@H]2CCCN2c2ccn3ncc(c3n2)C(=O)N1

CAS Number

2097002-61-2

Target & IC50

TrkA: ic50 0.6nM
TrkC: ic50 <2.5nM
Trk

Product Categories/Family for Selitrectinib, inhibitor

Tyrosine Kinase/Adaptors; Trk receptor

Product References and Citations for Selitrectinib, inhibitor

Drilon A, Nagasubramanian R, Blake J F, et al. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors[J]. Cancer Discovery, 2017, 7(9):CD-17-0507.

Other Notes

Small volumes of Selitrectinib, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Selitrectinib purchase

MBS5758331 is an inhibitor targeting Selitrectinib.